Gerstmann-Straussler-Scheinker disease (GSS): more detail

Which variants cause it, and what does that determine?

Several PRNP variants produce the GSS phenotype. P102L is the classical one and A117V the other common cause; the two most frequently named are those. Rarer variants include F198S and Y218N, and novel variants continue to be described.

Onset and duration are both described in the literature as largely variant dependent. Reviews give a mean duration of about 5 years and note that onset can occasionally be as early as the 20s; the CJD Foundation gives onset in the 30s to 50s and a duration of 2 to 10 years. P102L is among the variants described as nearly completely penetrant. Variant-level counselling therefore carries more information than a GSS diagnosis alone, and the reporting laboratory is the right source for what is known about the specific change in a family.

Inheritance is autosomal dominant, with a 50 percent chance of transmission to each child in current guidance. PRNP variants collects the variant-by-variant position, and genetic counselling comes first sets out the published sequence for well relatives.

How does it present?

The syndrome is anchored in cerebellar degeneration. GARD lists gait ataxia, dementia and cognitive impairment, dysarthria, lower limb weakness, reduced or absent tendon reflexes and paraesthesiae, with limb myoclonus uncommon. Reviews describe three recognised presentations: early cerebellar dysfunction, parkinsonism, or a frontotemporal dementia-like picture.

Two features separate GSS from sporadic CJD at the bedside. Cognitive decline tends to follow the motor syndrome rather than lead it, and myoclonus is not a reliable early sign. Pyramidal signs, spasticity, nystagmus and later visual and hearing problems appear as the illness extends.

The long course changes what care looks like. Falls, dysarthria, dysphagia and spasticity are managed over years rather than weeks, which brings in physiotherapy, speech and language therapy, orthotics and home adaptation alongside symptom control. Early palliative involvement is compatible with a multi-year illness and is recommended in prion disease generally. What to expect covers the care side.

Why do the standard CJD investigations mislead?

Because they were calibrated on rapidly progressive sporadic disease. Reviews state that periodic sharp wave complexes on EEG and CSF 14-3-3 are usually not detected in GSS, and that positive CSF RT-QuIC and MRI hyperintensity are seen only sometimes, depending on the variant. A normal EEG and a negative 14-3-3 in a slowly progressive ataxia therefore carry little weight against the diagnosis.

The 2026 Canadian comparison of seeding assays quantified the variant and substrate dependence on 116 diagnostic CSF samples (61 sporadic CJD, 50 inherited prion disease, 5 variably protease-sensitive prionopathy). A modified end-point assay using a deer mouse recombinant substrate gave 96.6 percent overall sensitivity and 100 percent specificity on the controls tested with it, against 87.1 percent for the standard hamster end-point assay and 72.4 percent for second-generation IQ-CSF RT-QuIC.

Within the GSS variants the pattern was: P102L 10 of 10 with the deer mouse substrate, 8 of 10 with the hamster end-point assay and 4 of 10 by IQ-CSF; A117V 1 of 1, 0 of 1 and 0 of 1; P105S 1 of 1, 1 of 1 and 0 of 1. Across the twelve GSS cases, 9 of 12 by the hamster assay became 12 of 12 with the modified substrate. The paper describes the hamster end-point assay as the accredited Canadian CSF test since 2016.

An earlier series of 56 CSF samples from genetic prion disease reported 78 percent sensitivity for P102L against 87 percent for E200K and 100 percent for D178N, from a listing in which the assay generation was not stated, so the ordering is more reliable than the individual figures.

Two practical conclusions follow. A negative CSF seeding result in a suspected GSS case should be recorded with the assay and substrate named, because the same sample can be positive or negative depending on which is used. And the quoted overall sensitivity in the 2026 paper deserves a check: the abstract reports 111 of 116 alongside 96.6 percent, which corresponds to 112 of 116.

Diagnosis in practice rests on the clinical picture, a three-generation family history, MRI, CSF studies and PRNP sequencing, with the gene test confirming. Sequencing of the coding region does not reliably detect octapeptide repeat insertions, which also produce GSS-like presentations at higher repeat numbers, so a suspected insertion needs a method chosen for it. How prion disease is diagnosed sets out the panel.

What is known about the neuropathology?

GSS is the prion disease defined histologically by multicentric PrP amyloid plaques, which is the feature that separated it from CJD before PRNP sequencing existed. Work on rarer variants has used patient-derived material to study the mechanism, including induced pluripotent stem cell cultures from a Y218N case that reproduced tau pathology, and mouse work on a novel variant that characterised a precursor for amyloidogenic 8 kDa PrP fragments. Those are mechanistic studies rather than clinical evidence, and GSS for researchers is where that literature belongs.

What reproductive options come up in these families?

They come up early, because onset in the 30s to 50s means many carriers learn their status while planning a family.

The published prion disease example is a 2014 JAMA Neurology case report. A 27-year-old asymptomatic woman from a GSS family, found on predictive testing to carry PRNP F198S, underwent IVF with preimplantation genetic diagnosis. Of 12 fertilised oocytes, polar body and blastomere analysis identified six without the variant; two were transferred and three viable embryos were frozen. A twin pregnancy followed, with slightly premature but healthy infants meeting developmental milestones at 27 months. The authors described it, to their knowledge, as the first published report of IVF with PGD for a genetic prion disease, and noted that non-disclosure PGD, in which the prospective parent does not learn their own genotype, was discussed as an option; this patient chose to know.

That is one family and one follow-up period, which is the whole of the published prion disease experience in this form at that time. Availability, funding and the rules on testing embryos differ by country, and the conversation belongs with a clinical genetics service. Family planning options and the right not to know cover the routes that do not require a parent to learn their status.

Where next?

Gerstmann-Straussler-Scheinker disease is the plain version for families, and current trials lists studies with sponsor-stated eligibility.

This page summarises published literature and is not clinical or genetic advice. No figure here describes the position of any particular person or family.